Mlecnik B, Bifulco C, Bindea G, et al. - Researchers assessed the prognostic worth of Immunoscore among patients with stage III colon cancer (CC) as well as investigated its link with the impact of chemotherapy on time to recurrence (TTR). Among 763 patients with American Joint Committee on Cancer/Union for International Cancer Control TNM stage III CC from cohort 1 (Canada/United States) and cohort 2 (Europe/Asia), the predefined consensus Immunoscore was assessed in an international study led by the Society for Immunotherapy of Cancer. TTR was analyzed as the primary endpoint. The lowest risk of recurrence was reported, in both cohorts, among patients with a high Immunoscore. At 3 years, patients with low, intermediate, and high immunoscores were found to have recurrence-free rates of 56.9%, 65.9%, and 76.4%, respectively. Findings demonstrated a significant correlation of a high Immunoscore with prolonged survival in stage III CC. It was also indicated that in terms of recurrence risk, chemotherapy will be the most beneficial in patients with a high Immunoscore.